Humco and Fagron have entered into a merger agreement combining the two companies for a value of up to $70 million.    The merger aims to add value to customers through Fagron’s extensive line of active pharmaceutical ingredients (APIs), product portfolio and strong research and development. While still working under the Humco brand, increased financial flexibility will facilitate continued investment into innovative pharmaceutical products for patients and pharmacies globally as w...